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Background: The mechanism mediating hormone-induced steroidogenesis involves multiprotein complexes.
Results: 14-3-3 is identified as a hormone-induced regulator of STAR function.
Conclusion: 14-3-3 negatively regulates steroidogenesis by interacting with STAR, acting in a buffer capacity to sustain the
STAR-mediated steroid formation for prolonged periods of time.
Significance: Characterizing the mechanisms regulating steroidogenesis contributes to our understanding of how steroids are
synthesized.
Cholesterol is the sole precursor of steroid hormones in the
body. The import of cholesterol to the inner mitochondrial
membrane, the rate-limiting step in steroid biosynthesis, relies
on the formation of a protein complex that assembles at the
outermitochondrialmembrane called the transduceosome.The
transduceosome contains several mitochondrial and cytosolic
components, including the steroidogenic acute regulatory pro-
tein (STAR). Human chorionic gonadotropin (hCG) induces de
novo synthesis of STAR, a process shown to parallel maximal
steroid production. In the hCG-dependent steroidogenic
MA-10 mouse Leydig cell line, the 14-3-3 protein was identi-
fied in native mitochondrial complexes by mass spectrometry
and immunoblotting, and its levels increased in response tohCG
treatment. The 14-3-3 proteins bind and regulate the activity of
many proteins, acting via target protein activation,modification
and localization. InMA-10 cells, cAMP induces 14-3-3 expres-
sion parallel to STAR expression. Silencing of 14-3-3 expres-
sion potentiates hormone-induced steroidogenesis. Binding
motifs of 14-3-3were identified in components of the transdu-
ceosome, including STAR. Immunoprecipitation studies dem-
onstrate a hormone-dependent interaction between 14-3-3
and STAR that coincides with reduced 14-3-3 homodimeriza-
tion. The binding site of 14-3-3 on STAR was identified to be
Ser-194 in the STAR-related sterol binding lipid transfer
(START) domain, the site phosphorylated in response to hCG.
Taken together, these results demonstrate that 14-3-3 nega-
tively regulates steroidogenesis by binding to Ser-194 of STAR,
thus keeping STAR in an unfolded state, unable to induce max-
imal steroidogenesis. Over time 14-3-3 homodimerizes and
dissociates from STAR, allowing this protein to inducemaximal
mitochondrial steroid formation.
Steroidogenesis is the result of a series of enzymatic reactions
mediating the metabolism of cholesterol to final steroid prod-
ucts in a tissue- and organelle-dependentmanner (1). The rate-
limiting step in steroidogenesis is the translocation of cholesterol
from cytosolic sources to the inner mitochondrial membrane,
where it ismetabolized to pregnenolone by the cytochrome P450
side-chain cleavage enzyme (CYP11A1). In adrenal glands and
gonads, steroid synthesis is induced by pituitary adrenocortico-
tropin and gonadotropin hormones, respectively. In Leydig
cells of testis, the luteinizing hormone/chorionic gonadotropin
(LH/CG) binds to the LH G-protein-coupled receptor), result-
ing in the rapid induction of the secondary messenger cAMP,
which in turn increases protein phosphorylation, protein syn-
thesis, andmobilization of cholesterol (2, 3). These actions ulti-
mately result in the assembly of a protein complex called the
transduceosome at the outer mitochondrial membrane
(OMM),4 through which import of cholesterol from the OMM
to the innermitochondrialmembrane occurs (4–6). The trans-
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duceosome consists of several cytosolic andmitochondrial pro-
teins, such as the translocator protein (18 kDa) TSPO, a high
affinity cholesterol- and drug-binding protein that plays a
major role in cholesterol import across the OMM (4). TSPO is
enriched at the contact sites of the inner mitochondrial mem-
brane and OMM along with another transduceosome protein,
the voltage-dependent anion channel (VDAC). It has been
demonstrated that several cytosolic proteins of the transduceo-
some, such as protein kinase A (PKA), acyl-CoA binding
domain-containing protein 3 (ACBD3, also known as PAP7),
and steroidogenic acute regulatory protein (STAR), assist in the
import of cholesterol to the inner mitochondrial membrane (4,
6). High levels of cAMP activate the PKA regulatory subunit
RI (PKARI), which is brought into the proximity of STAR
through its association with ACBD3. PKA RI is then able to
phosphorylate STAR (4, 7, 8). STAR (STARD1) is a 37-kDa
cytosolic protein that is expressed predominantly in gonads
and adrenal glands (9) and plays a significant role in steroido-
genesis (10–13). Upon hormonal stimulation, STAR levels
increase rapidly (9) This protein contains a mitochondrial sig-
nal sequence (62 N-terminal amino acids) that confines its
function to the OMM (14, 15). Phosphorylation of the Ser-194
residue of STAR increases its activity by 50%, resulting in max-
imal activity in steroid production (16–19). Import of STAR
from theOMMresults in the formation of the 30-kDa “mature”
STAR, which terminates its function (14, 19–21). The STAR C
terminus is a 210-amino acid hollow, hydrophobic, sterol bind-
ing domain called the STAR-related lipid transfer (START)
domain throughwhich STARbinds cholesterol with 3Maffin-
ity (10, 22–26). The presence of the START domain at the
OMM is sufficient to promote cholesterol transfer, as overex-
pression of STAR in steroidogenic cells has been shown to
increase pregnenolone formation in the absence of hormonal
stimulation (27). In steroidogenic cells, STAR expression is
tightly regulated (15, 28). Reduction or deletion of the Star gene
or knockdown of the STAR protein arrests steroidogenesis (27,
29, 30).Mutations of STAR lead to the development of congen-
ital lipoid adrenal hyperplasia, a condition in which cholesterol
accumulates in adrenal or gonadal cells (1, 29).
To further understand the changes occurring in steroido-
genic cell mitochondria in response to hormone treatment, we
analyzed native mitochondrial protein complexes from control
and hormone-treated MA-10 cells using mass spectrometry
and identified the presence of members of the 14-3-3 family of
proteins. The 14-3-3 proteins are small (27–32 kDa) acidic pro-
teins that are highly conserved across species (31–33). They act
as scaffolds and chaperones (33–35) and regulate cell signaling,
cell division, apoptosis, gene transcription, DNA replication,
and cytoskeletal formation and integrity. In mammals, seven
14-3-3 isoforms exist (36, 37). All 14-3-3 isoforms contain an
N-terminal dimerization domain through which they homo/
heterodimerize. Depending on the combination of dimers
formed, 14-3-3 proteins carry out distinct physiological func-
tions (38, 39). The 14-3-3 C terminus is the target binding
domain through which these proteins bind to more than 200
target proteins (40–42). Despite the high percentage of homol-
ogy between 14-3-3 isoforms, their targets are isoform-specific
(34). Based on our observation that 14-3-3 is increased 4-fold
upon hCG stimulation, we investigated the role of this protein
in the regulation of steroidogenesis and identified protein tar-
gets mediating its action in this pathway. The results demon-
strate that 14-3-3 binds to STAR and acts as a negative regu-
lator of steroid formation.
EXPERIMENTAL PROCEDURES
Cell Culture, Treatments, and Steroid Measurement—
MA-10 mouse Leydig tumor cells (kindly provided by Dr. M.
Ascoli, University of Iowa, Ames) were maintained in DMEM/
nutrient mixture F-12 (Invitrogen) supplemented with 5% fetal
bovine serum,2.5%horse serum, and1%penicillin and streptomy-
cin at 37 °C and 3.7% CO2. For the time-course experiments, cells
were incubated with cell culture media without serum, supple-
mented with 1 mM 8-bromo-cAMP (Enzo Life Sciences) or 50
ng/ml hCG (kindly provided by Dr. A. F. Parlow, the National
Hormone and Peptide Program, Harbor-UCLAMedical Center)
as indicated.The time-course treatmentwas carriedout for 15, 30,
60, and 120 min as indicated in the corresponding figures of each
experiment. To inhibit gene transcription, 10 g/ml actinomycin
D (Sigma) was added inmedia without serum in the presence of 1
mM cAMP.
When the trans-activator of transcription protein (TAT)
peptide was used, 1  103 MA-10 cells were cultured in Way-
mouthMB752/1medium containing 15% horse serum for 24 h.
The 250 nM TAT peptide treatments were performed for 90
min. For the 14-3-3 knockdown studies, 4 105 MA-10 cells
were plated in a gelatin-coated 100-mm cell culture dish and
incubated for 24 h. 5, 10, 20, and 50 nM 14-3-3 siRNA of a
mixture of 3 predesigned siRNAs (Table 1, Integrated DNA
Technologies) were tested. Hypoxanthine-guanine phosphori-
bosyltransferase siRNA was used at 10 nM as a positive control,
and a scrambled negative control was purchased from the same
provider. The optimal siRNA concentration of 20 nM was
selected for both 14-3-3 and scrambled siRNA. Cells were
incubated for 72 h in a mixture of 25 l of Lipofectamine
RNAiMAX (Invitrogen), 2.5 ml of Opti-MEM transfection
medium, and 2.5 ml of DMEM/F-12 media without antibiotic
supplemented with serum as previously explained. Progester-
one levels were measured by radioimmunoassay (RIA) in trip-
licate with beta counter LS5801 (Beckman). Protein levels in
each well were measured by using 1 N NaOH extraction buffer
and the Bradford dye assay (Bio-Rad) using a Beckman
spectrophotometer.
Mass SpectrometryAnalysis ofMitochondria—Mitochondria
were isolated by differential centrifugation as previously
described (6). Briefly, confluent MA-10 control cells were
treated with 50 ng/ml hCG for 2 h, washed twice with PBS,
harvested in buffer A (10mMHEPES-KOH (pH7.5), 0.2 Mman-
nitol, 0.07 M sucrose, 1 mM EDTA, and 1 Complete Protease
TABLE 1
Sequences used for siRNA
14-3-3 DsiRNA 1 5-CGCUUGUACUGUUUGGAAAUGACCT-3
3-GGGCGAACAUGACAAACCUUUACUGGA-5
DsiRNA 2 5-ACACUCAAUUGUAGUUUACAGUATT-3
3-AUUGUGAGUUAACAUCAAAUGUCAUAA-5
DsiRNA 3 5-CCACUAGGAAGAGGCAGUUCACUTG-3
3-UGGGUGAUCCUUCUCCGUCAAGUGAAC-5
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Inhibitor Mixture Tablets (Roche Diagnostics)) using a cell
lifter, and centrifuged at 500 g for 10 min. The cell pellet was
resuspended in 5 volumes of buffer A, incubated at 4 °C for 10
min, and then centrifuged at 500 g for 10 min. The cell pellet
was resuspended in 5 volumes of buffer B (40mMHEPES-KOH
(pH 7.5), 500 mM sucrose, 160 mM potassium acetate, and 10
mM magnesium acetate with 1 Complete Protease Inhibitor
Mixture Tablets) and homogenized using an electric Potter-
Elvehjem grinder (glass Teflon) for 10 passes. Cells were centri-
fuged at 500 g for 10 min. The cell pellet was resuspended in
5 volumes of buffer Bwith a glass-glass homogenizer (20 passes)
and centrifuged at 500  g for 10 min. The supernatant was
pooled and centrifuged at 10,000 g for 10 min at 4 °C to form
a mitochondrial pellet that was further resuspended in 1 ml of
buffer B and centrifuged at 10,000  g for 10 min to enrich
mitochondrial purity. The mitochondria were resuspended in
buffer B at a final concentration of 1 mg/ml. Blue native PAGE
(BN-PAGE) was performed as described by Simpson, in which
50 g of mitochondria, both control and treated, were pelleted
and solubilized with 1% digitonin buffer (20 mM Tris-HCl, 0.1
mM EDTA, 50 mM NaCl, 10% (w/v) glycerol, 1% digitonin
(Invitrogen), and 1 mM PMSF) for 20 min on ice. Mitochondria
were then centrifuged at 10,000 g for 10min. BN-PAGE load-
ing dye (5% (w/v) Coomassie Brilliant Blue G-250, 500 mM -a-
mino-n-caproic acid, and 160 mM Bis-Tris (pH 7.0)) was added
to the sample supernatants, loaded onto a 4–16% native gel
(Invitrogen), and run at 34 V overnight. The native gel spots cut
from control and hCG-treated mitochondria at 66 kDa were
in-gel-digested and analyzed via mass spectrometry as previ-
ously described (6), or the BN-PAGEwas further transferred to
a PVDF membrane for detection of 14-3-3 and - in native
mitochondrial complexes using 1:1000 dilutions of specific
antibodies (Santa Cruz Biotechnology). The membranes were
stripped using 8 ml of Restore Plus Western blot Stripping
Buffer (ThermoScientific) and reblotted using a 1:1000 dilution
of cytochrome c oxidase antibody (Abcam, Cambridge, UK).
Immunohistochemistry—Adult mouse testis sections (4–6
m; Cytochem Inc., Montreal, QC) were fixed using 4% form-
aldehyde for 20 min at20 °C. Cells were washed with 1 PBS
for 5 min at room temperature and permeabilized with 10%
Triton X-100 for 3 min. The sections were blocked with 10%
goat serum in a 1% BSA solution for 1 h at room temperature.
Cells were incubated overnight at 4 °C in a 1:50 dilution of
14-3-3 antibody in a humidified chamber. The following day
cells were washed with 1 PBS for 5 min at room temperature
twice and stained with secondary anti-rabbit IgG F(ab)2 frag-
ment (Alexa Fluor 488 conjugate; Invitrogen) for 1 h at room
temperature. Cells were washed, and a 1:250 dilution of
Hoechst (Enzo Life Sciences) was used for nuclear staining for
30 min at room temperature. Sections were maintained in one
drop ofmountingmedia (Invitrogen), and anOlympus inverted
microscope was used for imaging using 20 or 40 lenses.
Immunoblot Analysis—MA-10 cells (6  105 per well) were
cultured in 6-well gelatin-coated plates in triplicate for 24 h. A
cAMP time-course treatment was carried out. Cells were
washed twice in 4 ml of 1 PBS and harvested. Proteins were
extracted using radioimmune precipitation lysis buffer (Cell
Signaling Technology) or m-Per buffer (Thermo Scientific) in
transcription blocker experiments, and protein levels were
measured. Proteins (10 g) were solubilized in Laemmli load-
ing buffer and heated at 65 °C for 5–10 min. Samples were
loaded directly onto a 4–20% Tris-glycine polyacrylamide gel
(Invitrogen). Separated proteins were electrotransferred onto
PVDF membranes. Membranes were blocked using 10% milk
and blotted with a 1:1000 dilution of 14-3-3-specific or STAR
antibody (43) at 4 °C overnight. The following day the mem-
branes were washed with 1 Tween-Tris-buffered saline twice
at room temperature and incubated with secondary anti-rabbit
IgG HRP-linked antibody (Cell Signaling Technology) for 1 h
with shaking at room temperature to detect 14-3-3. Mem-
branes were developed using ECL streptavidin horseradish per-
oxidase conjugate (GE Healthcare) and imaged with a Fujifilm
LAS-4000. The membranes were further washed and stripped
using 8 ml Restore Plus Western blot Stripping Buffer at 37 °C
for 20 min, washed, blocked, and blotted with a 1:3000 dilution
of anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
antibody (Trevigen) overnight at 4 °C as a loading control. Rel-
ative expression of proteinswas assessed bymeasuring the band
intensity (AU) and background intensity (BG) for each lane and
calculating (AU-BG)/mm2.
Quantitative Real-time PCR Analysis—MA-10 cells (2 105
per well) were cultured in 12-well gelatin-coated plates in trip-
licate and incubated overnight to reach 90% confluency. Time-
course treatment with cAMP was performed. Cells were
washed with 1 ml 1 PBS and harvested. RNA was extracted
using RNeasyMini kit (Qiagen). ThemRNA concentration was
measured with a Nanodrop 1000 spectrophotometer (Thermo
Scientific). Exactly 1 g of total RNA was used for RT-PCR
using random hexamer primers (Roche Diagnostics) according
to the manufacturer’s manual. Quantitative PCR (qPCR) was
conducted using 2 l of RT-PCR product with LightCycler 480
SYBR Green I Master Mix (Roche Diagnostics), and primers
were purchased from Integrated DNA Technologies (Table 2).
Hypoxanthine-guanine phosphoribosyltransferase primers
were used as an endogenous control at the each time point of
cAMP treatment. Quantitative PCR was performed in tripli-
cate, and the Ct method was used to demonstrate the rela-
tive transcription of the target gene compared with the refer-
ence gene.
Immunocytochemistry and Confocal Microscopy—MA-10
cells (2  104 per well) were plated in 96-well glass-bottom
dishes (Fluorodish, WPI, Sarasota, FL) in triplicate and incu-
bated until 60% confluent. Time-course treatment with cAMP
was performed. Cells were fixed with 4 °C methanol for 3–5
min, permeabilized with 10% Triton X-100 for 3 min, and
blockedwith 10% goat serum for 1 h at room temperature. Cells
were incubated in a 1:25 dilution of 14-3-3 antibody and 5
TABLE 2
Quantitative PCR primers used
HPRT, hypoxanthine-guanine phosphoribosyltransferase.
14-3-3 Forward CGGACAGAAGAAGATCGAGATGGTCCG
Reverse GTTGTCCAGCAGGCTCAGCA
STAR Forward ACCAGGAAGGCTGGAAGAAGGAAA
Reverse ACCAGGAAGGCTGGAAGAAGGAAA
HPRT Forward GCGTCGTGATTAGCGATGATGAAC
Reverse ACCGACTGGATGGCTGATGAATGA
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g/ml cytochrome c oxidase antibody (Abcam) overnight at
4 °C. The next day the wells were washed with 1 PBS and
stained with secondary anti-rabbit IgG F(ab)2 fragment (Alexa
Fluor 488 conjugate) and anti-mouse IgG F(ab)2 fragment
(Alexa Fluor 555 conjugate; Cell SignalingTechnology) at room
temperature for 1 h. Cells werewashedwith 0.5 MTris-HCl (pH
7.6), and an appropriate concentration of DAPI was used for
nuclear staining for 5 min at room temperature. Cells were
maintained in ultra-pure water. Confocal microscopy was per-
formed using an Olympus Fluoview FV1000 laser confocal
microscope with a 100 lens. Images were imported into Corel
DrawX5 software, and images of representative cells from each
well were selected.
Cross-linking—MA-10 cells (1  106 per Petri dish) were
plated in gelatin-coated 100-mm Petri cell culture dishes
overnight to reach 90% confluency. Medium was replaced
with Dulbecco’s modified Eagle’s limiting medium supple-
mented with 10% FBS and 105 mg/liter photo-leucine and 30
mg/liter photo-methionine (Thermo Scientific). Cells were
incubated for 22 h followed by cAMP time-course treatment.
Medium was decanted and replaced with 4 ml of 1 PBS.
Cross-linking was performed immediately using a 3UV lamp
(UVP) for 16 min at 365 nm at a distance of 1 cm from the
surface of the Petri dishes.
Co-immunoprecipitation—Co-immunoprecipitationwas per-
formed using a Dynabeads co-immunoprecipitation kit (Invitro-
gen). The antibody coupling process was performed using
14-3-3 antibody following the manufacturer’s recommenda-
tions, yielding 10 mg/ml antibody-coupled beads. Cross-
linked protein lysates of MA-10 cells were harvested accord-
ing to the manufacturer’s recommendations. Proteins were
collected in extraction buffer A (containing 1 immunopre-
cipitation buffer, 1 M NaCl, and protease inhibitor tablets
without EDTA) and 0.5 mg of protein was precipitated with
150 l of 10 mg/ml antibody-coupled beads rotating at 4 °C
for 1 h. When studying 14-3-3 dimerization, 0.1 mg of the
protein lysate was used for co-immunoprecipitation. The
precipitated samples were loaded on 4–20% Tris-glycine
gels. MA-10 protein (10 g) was used in the native state
before and after 2 h of cAMP treatment (indicated on the gels
as IB and NCL) or in the cross-linked state before and after
2 h of cAMP treatment (indicated on the gels as IB and CL).
The immunoblot analysis was carried out as previously
described, and the following antibodies and dilutions were
used to blot the membranes: anti-14-3-3 and anti-14-3-3
(1:1000 dilutions, Santa Cruz Biotechnology), anti-TSPO
(1:5000 dilution (8)), anti-STAR (1:2000 dilution), and anti-
ACBD3 (1:1000 dilution (44)), anti-PKARI (1:1000 dilu-
tion, Santa Cruz Biotechnology), and anti-VDAC1 (2 g/ml,
Abcam). Secondary antibodies were used at the dilution fac-
tors previously mentioned.
Duolink andConfocalMicroscopy—MA-10 cells (1 103 per
well) were cultured in a 96-well glass-bottom dish (Fluorodish,
World Precision Instruments) in triplicate and incubated over-
night. Cells were treated in a time-course with cAMP as previ-
ously discussed. Cells were fixed using 3.7% formaldehyde for
15 min in 37 °C, washed with 1 PBS twice at room tempera-
ture, and permeabilized with 10% Triton X-100 for 1 min at
room temperature. The Duolink II Red Starter Kit (Olink Bio-
science) was used following the manufacturer’s recommenda-
tions. Primary antibodieswere used in combinations of 14-3-3
(anti-mouse; Santa Cruz Biotechnology) and STAR (anti-rab-
bit) or 14-3-3 (anti-mouse and anti-rabbit) overnight at 4 °C.
Mitochondria and nuclei were stained using Mito-ID and
Hoechst, respectively, both in 1:250 dilutions (Enzo Life Sci-
ences) for 30min at 37 °C. Cells werewashed andmaintained in
ultra-pure water. An Olympus Fluoview FV1000 laser confocal
microscope equipped with a 100 lens was used to detect pro-
tein-protein interactions between 14-3-3 and either STAR or
itself. Z stacks were captured from the bottom to the top of the
cell nucleus. Images were imported into Corel Draw X5 soft-
ware, and the images of representative cells from eachwell were
selected.
Peptide Design and Labeling—Peptides were designed to
contain an 11-mer of the HIV-1 TAT followed by a glycine
residue and 15, 14, or 13 amino acids containing the 14-3-3
binding sites I, II and III, respectively, from theMus muscu-
lus STAR protein (Table 3). Peptide I was synthesized by
Bachem, and peptides II and III were synthesized by the
Sheldon Biotechnology Center at McGill University, Que-
bec. Peptide labeling was carried out using the Oregon Green
Labeling kit (Invitrogen), and the protein concentration and
degree of labeling (mol of dye/mol of protein) were assessed
by measuring absorbance at 280 and 496 nm using a Beck-
man spectrophotometer.
In Silico 14-3-3 Binding Motif Analysis—The presence of
14-3-3 binding motifs was assessed using uniprot motif scan to
detect the 14-3-3 binding motif mode I (RSXpSXP, where R is
arginine, S is serine, X is any amino acid, P is proline, and T is
threonine), whereas mode II (RXXXpSXP) was detected manu-
ally (40, 42, 45).
Statistical Analysis—All experiments were performed in
triplicate with three significant cell passages. RIA and qPCR
have been performed in triplicate for each passage as well. The
two-tailed unpaired t test was used for the immunoblot, and
qPCR statistical analyses and a one-way ANOVA test was used
for statistical analyses of the effect of the transcription inhibitor
and protein-protein interaction studies.
TABLE 3
TAT peptide sequences and proposed binding sites
CAH, congenital adrenal hyperplasia.
No. TAT peptide Motif
Amino
acid Site Mr
Da
I YGRKKRRQRRRGMGQVRRRSSLLGSQL 14-3- Mode I 52–58 Cleavage site (37/32/30 kDa) 3286.88
II YGRKKRRQRRRGPGVLRDFVSVRCTK 14-3- Mode II 181–187 Mutation leads to CAH 2950.5
III YGRKKRRQRRRGCTKRRGSTCVLAG 14-3- Mode II 191–196 Phosphorylation increases STAR activity; mutation leads to CAH 3175.8
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RESULTS
Mass Spectrometry Identifies Presence of 14-3-3 Proteins in
MA-10 Mitochondria—To identify proteins that may play a
role in cholesterol import, mitochondria were isolated from
control or hCG-treated (for 2 h) MA-10 cells. The mitochon-
drial protein complexes were separated by BN-PAGE, and the
major 66-kDa protein complex was analyzed using mass spec-
trometry (Fig. 1A). The results indicated the presence of mem-
bers of the 14-3-3 protein family (, ,,, and ) in the 66-kDa
protein complex. However, only 14-3-3 and - levels were
increased after hCG treatment of the cells (4- and 1.6-fold,
respectively). The presence and hormonal regulation of both
isoforms at themitochondriawere further confirmed by immu-
noblot analysis of the BN-PAGE-separated proteins (Fig. 1B).
The 4-fold induction by hCG of 14-3-3 levels in mitochondria
estimated by the number of MS hits was confirmed by BN-
PAGE immunoblot analysis. However, a large 6-fold induc-
tion of 14-3-3 levels was seen by BN-PAGE immunoblot anal-
ysis in hCG-treated mitochondria, in contrast to 1.6-fold
increase in the number of MS hits found for the protein. This
discrepancy may be due to the fact that proteins in BN-PAGE
retain their native folding, and thus, hCG treatment may have
allowed for better exposure of the 14-3-3 immunoreactive
epitopes. Immunohistochemistry of adultmouse testis sections
confirmed the presence of 14-3-3 in interstitial Leydig cells of
the testes (Fig. 1C).
Expression of 14-3-3 in MA-10 Cells—To characterize the
14-3-3 expression pattern and localization inMA-10 cells, we
stimulated the cells with cAMP in a time-course of up to 2 h.
Immunoblot analysis demonstrated that the levels of 14-3-3
FIGURE 1.Presenceof 14-3-3 in native complexes ofMA-10 cellmitochondria and testis of adultmouse.A, BN-PAGEof nativemitochondrial complexes
from control and hCG-treated cells is shown. Mass spectrometry analysis indicated the presence of the 14-3-3 family of proteins in the mitochondrial 66-kDa
complexes. Thepresenceof theproteins in control versushCG-treatedcells is shownasmass spectrometry (MS)hits in the secondand third column.B, BN-PAGE
followed by dry transferring to PVDFmembranes indicates the presence of 14-3-3 and - inMA-10 cell mitochondria before and after hCG stimulation for 2 h.
Relative expression of 14-3-3 compared with the mitochondrial protein control cytochrome c oxidase (COXIV) is shown in the bar graph. C, immunohisto-
chemistry of adult mouse testis sections shows the expression of 14-3-3 in interstitial cells.
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increased after 1 h of cAMP treatment (Fig. 2A) or hCG (data
not shown). This pattern was similar to that of STAR, a protein
that is known to be rapidly induced in response to hormonal
treatment (Fig. 2A). We then measured by qPCR the levels of
mRNA for both STAR and 14-3-3 with the same time-course
treatment. The results indicated that mRNA levels of both pro-
teins are induced only after 120 min of treatment (Fig. 2B),
implying that the increase in protein levels of 14-3-3 and
STAR at earlier time points are likely due to the presence of
pre-existing mRNA. To test this hypothesis we incubated the
cells for different time periods in the presence of the transcrip-
tion inhibitor actinomycin D to block new mRNA synthesis in
FIGURE2.The transcriptionandexpressionpatternof14-3-3 is similar to thatofSTAR.MA-10cellswere stimulatedwith1mMcAMP ina time-coursewith
the indicated time points. A, protein levels of STAR (white bars) and 14-3-3 (gray bars) were assessed by immunoblot analysis. Representative immunoblots
from three independent experiments show 14-3-3, STAR, and control GAPDH protein levels at 0, 30, 60, and 120min after cAMP treatment. A.U., absorbance
units. B, levels ofmRNAof both STAR (white bars) and 14-3-3 (gray bars) were assessed by qPCR in triplicate. GAPDHmRNA levelswere used for normalization.
Results shown are themeans S.D. from three independent experiments performed in triplicates. C, MA-10 cells were treatedwith the transcription inhibitor
actinomycin D (10 g/ml) and cAMP (1 mM). At the indicated time points cells were collected, and the expression levels of 14-3-3, STAR, and the control
GAPDH were assessed by immunoblot analysis. Representative immunoblots from three independent experiments show 14-3-3, STAR, and control GAPDH
protein levels at 0, 30, 60, and 120min after cAMP treatment.D, localization of 14-3-3 inMA-10 cells by immunocytochemistry is shown.DAPI, Alexa Fluor 488,
and Alexa Fluor 555 were used to indicate nuclei, 14-3-3, and mitochondrial cytochrome c oxidase, respectively. The merge channel indicates that 14-3-3
partially colocalizes with mitochondria.
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the presence of cAMP. Immunoblot analysis demonstrated the
presence of pre-existing mRNA for both 14-3-3 and STAR as,
despite inhibiting gene transcription, the levels of both proteins
were induced by cAMP (Fig. 2C). However, distinct cAMP-
induced time-dependent patterns of 14-3-3 and STARprotein
expression were seen (Fig. 2C). To characterize the localization
pattern of 14-3-3 in MA-10 cells, we performed the same
time-course treatment with cAMP and fixed the cells. Immu-
nofluorescence analysis demonstrated that 14-3-3 is present
in MA-10 cells and partially colocalizes with mitochondria as
shown by its colocalization with the mitochondrial protein
cytochrome c oxidase (Fig. 2D).
Decrease in 14-3-3 Expression Increases Steroidogenesis—
To investigate the role of 14-3-3 in steroidogenesis, we assessed
the ability of the cells to form steroids after siRNA knockdown of
14-3-3. After 72 h of treatment with 20 nM 14-3-3-specific
siRNA, immunoblot analysis of the cell lysates showed a 55%
reduction in14-3-3protein levels (Fig. 3A).TheMA-10cellswith
reduced levels of 14-3-3 were then treated with saturating con-
centrations of hCGor cAMP, and progesterone levels weremeas-
ured by RIA. The results indicate that the decrease in 14-3-3
protein levels results in increased steroid production (Fig.
3B). This effect was specific to 14-3-3 siRNA used and
could not be reproduced by scrambled siRNA (Fig. 3B).
When these data were analyzed by calculating the increase in
progesterone production between two consequent time
points as shown in Fig. 3C, it became clear that the rate of
progesterone synthesis significantly increased between 0
and 30 and between 30–60 min but not between 60 and 120
min of cAMP simulation. Thus, the significant increase seen
after 120 min in Fig. 3B represents progesterone accumula-
tion rather than increased rates of progesterone synthesis, as
is the case for the earlier time periods. Similar results were
obtained with hCG treatment (Fig. 3D). These experiments
suggested a time-dependent negative regulatory role for this
protein in MA-10 cells.
FIGURE 3. Role of 14-3-3 in steroidogenesis. A, MA-10 cells were treated with different concentrations of 14-3-3 isoform-specific siRNA and analyzed by
immunoblot analysis. A representative immunoblot from three independent experiments is shown. A.U., absorbance units. HPRT, hypoxanthine-guanine
phosphoribosyltransferase. B, time-course treatment of MA-10 cells with 1 mM cAMP followed by RIA to measure progesterone levels in control cells (white
bars), cells transfected with 20 nM scrambled siRNA (light gray bars), and cells treated with 20 nM 14-3-3 siRNA (dark gray bars) is shown. C, data obtained in B
was further analyzed to assess the rate of progesterone synthesis between the indicated timepoints (0–30, 30–60, and60–120min).D, time-course treatment
ofMA-10 cells with 50 ng/ml hCG is shown. Data obtainedwas analyzed to assess the rate of progesterone synthesis between the indicated time points (0–30,
30–60, and 60–120 min). Results shown are means S.D. from at least three independent experiments performed in triplicate.
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Identification of 14-3-3 Target Proteins by Co-immuno
precipitation—The majority of 14-3-3 target proteins contain
14-3-3 binding motifs present in three subtypes: modes I, II,
and III (optimal motifs) and/or variations of these three modes
(suboptimal motifs). We performed an in silico analysis to
screen for the presence of 14-3-3 binding motifs on proteins
known to play a role in steroidogenesis and identified mainly
motifs of suboptimal modes I and II. One or more of these
binding sites were found within STAR, TSPO, ABCD3,
PKARI, and VDAC (Fig. 4A). Because this analysis is not iso-
form-specific, further identification of 14-3-3-specific targets
was performed by co-immunoprecipitation using 14-3-3 anti-
sera followed by immunoblot analysis with the indicated
antibodies.
Considering the transience of the interaction between 14-3-3
proteins and their targets and the presence of suboptimal
motifs on the transduceosome components, photo-activatable
amino acids were used to cross-link 14-3-3 and its target pro-
teins by UV irradiation after stimulation of MA-10 cells with
cAMP at the indicated time points. The results showed that
14-3-3 binds to TSPO, VDAC, PKARI, ACBD3, and 14-3-3
without cAMP or time dependence (Fig. 4B), whereas 14-3-3
association/dissociation with STAR (Fig. 4B) and its
homodimerization pattern (Fig. 4C) are time-dependent after
cAMP treatment with inverse binding properties. In the
absence of cAMP treatment, 14-3-3 homodimers are present,
and there is no detectable interaction with STAR. Upon 15min
of cAMP stimulation, 14-3-3 homodimer levels are reduced,
and its association with STAR is observed. The pattern of
reduced levels of homodimerization and higher levels of STAR
association ismaintained up to 60min of cAMP stimulation. At
120 min, the binding of STAR to 14-3-3 is significantly
reduced, whereas 14-3-3 homodimer levels are increased
compared with previous time points (Fig. 4, C and D).
FIGURE 4. In silico and in vitro identification of 14-3-3 target proteins in the transduceosome complex. A, in silico analysis shows the presence of
suboptimal 14-3-3 binding motifs of mode I and II in STAR, VDAC, PKARI, and ABCD3. B, MA-10 cells were treated with 1 mM cAMP. Cross-linking was
performed using photoactivatable amino acids in cell culture media and exposure to UV light after cAMP stimulation as indicated under “Experimental
Procedures.” Approximately 0.5 mg protein was co-immunoprecipitated (IP) with 14-3-3 antibody followed by immunoblot analysis (IB) using anti-
bodies for TSPO, VDAC, ABCD3, PKARI, and 14-3-3. C. Treatments were performed as described above (B), and STAR antibody was used to study
binding between STAR and 14-3-3. D, treatments were performed as described above (B), and the homodimerization pattern of 14-3-3 was studied
by using the same antibody for both co-immunoprecipitation of 0.1 mg of protein and immunoblot. In C and D relative expression of proteins was
analyzed as described under “Experimental Procedures.” All results shown are representative of at least three independent experiments. A.U., absorb-
ance units. Cross-linked samples are indicated as CL and not cross-linked as NCL.
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Identification of 14-3-3 Target Proteins by In-cell
Immunoprecipitation—Toconfirmthepatternof14-3-3-STAR
interaction and compare it to that of 14-3-3 homodimerization,
we performed in-cell immunoprecipitation using Duolink tech-
nology followed by confocal microscopy. In this technique,
interactions between the proteins of interest are shown as red
fluorescent signals due to secondary antibody-linked oligonu-
cleotide ligation and amplification, indicative of the interaction
between the proteins recognized by the primary antisera. By
comparing the intensity of signals at different time points after
hormone treatment usingOlink imaging software, the 14-3-3-
STAR interaction and 14-3-3 homodimerization were
observed. Homodimerization of 14-3-3 was seen at 0 and 120
min (Fig. 5, A and C). The results confirm the previous co-
immunoprecipitation data (Fig. 4C) and demonstrate that the
14-3-3-STAR association is a time-dependent event showing
an inverse pattern to that of 14-3-3 homodimerization. Fig. 5E
shows the negative control without primary antibody.
Identification of 14-3-3 Site(s) of Interaction with STAR—
Wepreviously identified (Fig. 4A) in silico14-3-3bindingmotifs of
mode I (amino acids 52–58) and ofmode II (amino acids 181–187
and 191–196) on STAR (Fig. 6A). To assess the functionality of
these 14-3-3 binding sites on STAR, these sequences were conju-
gated to an 11-mer TAT peptide (Fig. 6B; Table 3), a part of the
HIV transcription factor TAT that can easily penetrate cell mem-
branes and, therefore, acts as a shuttle for the conjugated
sequence. Oregon Green-labeled peptides were found to be rap-
idly (within 15 min of treatment) transduced into the cells (Fig.
6B). Cells were treated for 15 min with cAMP to yield maximal
STAR-14-3-3 interaction (as shown in Figs. 4C and 5,A and B).
FIGURE5.Confirmationof STAR-14-3-3 interactionsusingDuolink technology.A,MA-10 cellswere treatedwith 1mMcAMP in a time-course as indicated.
Duolink technology was performed using rabbit anti-STAR antibody and mouse anti-14-3-3 antibody followed by the addition of proximity ligation assay
probes. The red fluorescent tagwas used to detect 14-3-3-STAR interactions, Hoechst for nuclei staining, andMito-ID formitochondrial staining. B, the signal
per cell ratiowas assessed for each time point usingOlink software and normalized to the time point with themaximum interaction (15min). C andD, a similar
experiment was performed using two 14-3-3 antibodies, raised in mouse and rabbit. The signal per cell ratio was measured and compared with that of the
time point with the highest ratio (120 min). E, the experiment was performed as before, only in the absence of primary antibody to indicate background
staining. Results shown are representative of at least three independent experiments.
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The interaction between 14-3-3 and STAR was assessed
using Duolink technology and confocal microscopy (Fig. 6C).
These results indicated that the peptide containing the first
14-3-3 binding motif (mode I, amino acids 52–58) on STAR
does not compete with STAR protein for interaction. The pep-
tide containing the second 14-3-3 binding motif (mode II,
amino acid 181–187), despite partial competition with STAR,
did not significantly block the interaction between STAR and
14-3-3. However, the third peptide (mode II, amino acids
191–196) significantly competed with STAR and blocked the
STAR-14-3-3 interaction by 80% (Fig. 6C). MA-10 cells were
then incubated with media containing 250 nM of the STAR-
competing peptide followed by cAMP treatment for 15, 30, and
60 min, which are the time points during which STAR and
14-3-3 interact (Fig. 4C and 5, A and B), and progesterone
formation was measured. The results indicated that the nega-
tive regulatory role of 14-3-3 is carried out through its inter-
action with STAR.When this interaction is inhibited due to the
presence of a STAR-competing peptide, MA-10 cells produce
higher levels of progesterone (Fig. 6D). Calculation of absolute
values of progesterone formation between each two conse-
quent time points showed an increasing rate of progesterone
synthesis that reaches significantly higher levels between 30
and 60 min after cAMP treatment (Fig. 6E).
DISCUSSION
Hormonal induction of cholesterol import into mitochon-
dria and thus steroidogenesis are mediated by the multiprotein
complex known as the transduceosome. This complex is com-
posed of mitochondrial and cytosolic proteins that contribute
to the import of cholesterol into mitochondria, the rate-limit-
ing step in steroid biosynthesis in the adrenal glands and gonads
(1, 3, 4, 46). The transduceosome is formed of the OMM pro-
teins TSPO and VDAC and the cytosolic proteins PKARI,
FIGURE 6. Identification of the 14-3-3 binding site on STAR. A, the 14-3-3 binding motif mode I (residues 52–57) and mode II (residues 181–187 and
191–196) were detected in silico on STAR. Peptides containing a TAT peptide sequence followed by each of the 14-3-3motifs on STARwere synthesized (Table
3). B, peptide labeling using Oregon Green 488 shows that TAT peptide sequences easily penetrate the MA-10 cell membrane and enter the cytoplasm,
therefore acting as a shuttle for the 14-3-3 binding motifs on STAR. C, MA-10 cells were treated with 1 mM cAMP for 15 min to induce maximal STAR-14-3-3
interactions. The top panel shows the control cells. In the second, third, and fourth panel, cells were treated for 90min with 250 nM concentrations of the first,
second, and third peptides, respectively, followed by 15 min of cAMP treatment. Duolink was performed using mouse anti-14-3-3 antibody and rabbit
anti-STAR antibody. The signal per cell was measured and normalized to the control, indicating that only peptide three significantly competes with STAR
interaction with 14-3-3 and blocks this interaction. D, levels of progesterone were measured in MA-10 cells treated with 250 nM of the STAR-competing
peptides. Cells were treated with cAMP for 15–60 min to induce STAR-14-3-3 binding, and progesterone levels were measured. E, data obtained in D were
analyzed to assess the rate of progesterone synthesis between the indicated time points (0–15, 15–30, and 30–60 min). Results shown are the means S.D.
from at least three independent experiments performed in triplicate. Binding site I, II, and III indicate the corresponding peptide I, II, and III used.
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ACBD3 (a member of the protein kinase A-anchoring pro-
teins), and the hormone-induced and -activated STAR (4, 47,
48). The function of the transduceosome is to mediate and
amplify the cAMP signal (48) at the cytosol/mitochondrion
interface. Indeed, STAR functions at the OMM, and phospho-
rylation of this protein has been shown to be essential for its role
in cholesterol mobilization across the OMM. Two PKA con-
sensus sequences have been identified on STAR at Ser-55 and
Ser-194 (7). Phosphorylation of the first serine residue is linked
to the cleavage of the mitochondrial signal sequence of STAR,
whereas phosphorylation of the second serine residue is
responsible for maximal activity of the protein, which is
required for steroidogenesis (16, 24). Therefore, STAR levels
are tightly regulated in steroidogenic cells, and understanding
the mechanisms underlying its regulation would provide
insights into transduceosome protein-protein interactions and
the regulation of steroidogenesis.
To find possible candidates that contribute to the regulation of
steroidogenesis, native mitochondrial complexes of control and
hormone-treated MA-10 Leydig cells were analyzed using mass
spectrometry, which revealed the presence of members of the
14-3-3 family of proteins. A 4-fold induction in 14-3-3 levels was
observeduponhCGstimulation.The14-3-3protein isknownfor
its roles in regulating intracellular protein localization (49), the cell
cycle, cell division, apoptosis (50), and mitogenic signaling (51) as
well as its involvement in diseases such as Parkinson disease (52)
and cancer (53). This protein has recently been identified as an
oncogene (53, 54). Considering thatMA-10 cells are amouse Ley-
dig cell line, we investigated and demonstrated the presence of
14-3-3 in interstitial Leydig cells of the adult mouse testis. Based
on themass spectrometry results, the observation that 14-3-3pro-
teins associatewithmitochondria, and the increase in 14-3-3 lev-
els upon cAMP treatment, we investigated whether 14-3-3 plays
a regulatory role in steroidogenesis.
Our studies demonstrate that 14-3-3 is widely distributed
within MA-10 cells and partially co-localizes with mitochon-
dria. The transcription/translation pattern of 14-3-3 is similar
to that of STAR; both proteins are encoded by pre-existing
mRNAs that are acutely translated upon cAMP stimulation.
Interestingly, translation of pre-existing Star mRNA was
induced by cAMP in a time-dependent manner with protein
synthesis increasing over time and beyond 2 h upon cAMP
treatment. However, the cAMP-induced translation of pre-ex-
isting 14-3-3mRNA rapidly reachedmaximal levels at 30min,
suggesting that the mechanisms mediating the cAMP-induced
translation of these two pre-existing mRNAs are distinct.
To understand the physiological role of 14-3-3 in steroido-
genic Leydig cells, we measured and compared steroid forma-
tion when 14-3-3 levels were reduced after siRNA treatment.
Progesterone formation in MA-10 cells was increased when
14-3-3 levels were reduced, suggesting a negative regulatory
role for this protein in steroidogenesis. Knockdown of 14-3-3
led to a shift in the time frame of steroid production, as proges-
terone levels produced at each time point in the presence of
14-3-3was comparablewith that of an earlier time point in the
absence of 14-3-3. Further analysis of the data showed that
14-3-3 acts during distinct periods of time after cAMP treat-
ment, indicating a transient effect.
It has been previously shown that 14-3-3 proteins act as scaf-
folds through protein-protein interactions, inhibit protein
modifications, alter the intrinsic activity of their target proteins,
and alter the subcellular localization of their target proteins (33,
55). Through in silico and in vitro protein-protein interaction
analysis, we identified STAR, TSPO, ACBD3, PKARI, and
VDAC as targets of 14-3-3. Therefore, we introduce 14-3-3
as a newmember of the transduceosomemultiprotein complex.
Based on the adaptor characteristics of this protein, it is possi-
ble that 14-3-3 plays a role in the assembly of the transduceo-
some complex. In vitro and in-cell co-immunoprecipitation
experiments revealed that 14-3-3 does not interact with STAR
in control MA-10 cells. However, hormonal treatment of the
cells triggers the association of 14-3-3monomers with STAR
for 15–60min after treatment, a periodwhen 14-3-3may play
a negative regulatory activity on steroidogenesis.
Previous studies indicated that, although STAR levels are
induced as early as 60 min upon hormonal stimulation, steroid
formation reachesmaximal levels no earlier than 2 h after stim-
ulation (2, 56). The results presented herein suggest that this
delay is based on the association of STARwith 14-3-3, leading
to inhibition of STAR activity before 2 h post-stimulation.
Becausemost likely not the entire STAR formed associates with
14-3-3, the available free STAR would exert some steroido-
genic function without, however, reaching maximal activity.
These results may also explain the reported lag between accu-
mulation of the 37-kDa STAR and increase in pregnenolone
production (1, 3, 4, 46). Dissociation of 14-3-3 from STAR
allows STAR to carry out its function at the maximal level, and
therefore, high levels of steroids are produced under these con-
ditions. Thus, 14-3-3 seems to act in a buffer capacity to sus-
tain the hormone- and cAMP-induced signal mediated by
STAR for a longer period of time.
We further addressed the mechanism underlying 14-3-3
dissociation from STAR after 2 h. Previous studies by Aitken et
al. (34, 57, 58) showed that 14-3-3 has a 95% tendency to form
homodimers(33, 59). Our data suggest that 14-3-3 dimeriza-
tion occurs when the protein dissociates from STAR at 2 h after
cAMP treatment. These studies suggest that 14-3-3 is present
as both homodimers and heterodimers with 14-3-3, in control
cells. Upon 15 min of cAMP stimulation, 14-3-3 protein
expression is increased, and homodimerization is reduced,
whereas heterodimerization with 14-3-3 remains unaltered.
Therefore, high levels of 14-3-3monomers are present, avail-
able to bind to STAR from 15 to 60min post-treatment. At 120
min post-treatment, the high levels of cAMP-induced 14-3-3
adopt a homodimeric conformation, likely displaying a domi-
nant negative regulatory role, a well studied function of the
14-3-3 family of proteins (57–59). The structure, significant
functional domains, and modification sites of STAR are well
studied (10, 60). Therefore, identification of the site(s) of
14-3-3 binding to STAR would provide insight into how the
interaction between the two proteins occurs. We identified
in silico the presence of three 14-3-3 binding motifs in three
critical regions of STAR. These binding sites are placed at sites
essential for (i) proteolytic cleavage from the 37-kDa form of
the protein to the 32-kDa “intermediate, active” form and
the 30-kDa “mature, inactive” form (1), (ii) activity (the site
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includes theArg-182 residue,which ifmutated leads to congen-
ital adrenal hyperplasia) (16, 29, 29), and (iii) maximal activa-
tion (the site includes the Ser-194 residue, which is phospho-
rylated for maximal activity). These 14-3-3 binding motifs are
of mode I and II. Several studies indicate that 14-3-3 protein
targets contain optimal or suboptimal motifs as a result of
adapting to their physiological requirement to transient bind-
ing and dissociation from 14-3-3 proteins (42, 45, 61). The
majority of 14-3-3 targets, including STAR, contain suboptimal
motifs (45, 57). To identify the specific 14-3-3 binding site(s)
on STAR, transducible peptides containing each of the three
candidate 14-3-3-binding peptide sequences were used to
assess the competition efficiency of each sitewith intact, endog-
enous STAR protein. The results indicate that, despite compe-
tition from at least two 14-3-3 bindingmotifs with STAR, only
one of the peptides significantly reduced STARbinding to 14-3-
3. This motif is of mode II and contains the Ser-194 residue,
which is essential for STAR phosphorylation and activation by
PKA. Previous studies have suggested that the point mutation
S194A reduces activity of STAR by 50% (16). It should be noted
that 14-3-3-specific binding to the PKA consensus peptide
sequence (R(R/K)X(S/T)) containing Ser-55 was not observed,
suggesting that 14-3-3 regulation of STAR activity is specific
for the Ser-194 phosphorylation site rather than a general asso-
ciationwith serine residues in a PKA consensus site. Treatment
of MA-10 cells with the transducible peptide and further stim-
ulation of these cells for 15–60 min with cAMP, the period of
STAR-14-3-3 interaction, showed an increase in steroid for-
mation compared with control cells. This increase was trig-
gered as early as 15min and peaked after 60min of stimulation,
indicating that the specific role of 14-3-3 in the negative reg-
ulation of steroidogenesis is through its association with and
inhibition of STAR.
The specific 14-3-3 binding motif on STAR structure falls in
a STAR region conserved across mammalian species (19, 62).
Considering that the 14-3-3 family of proteins is highly con-
served across species (63), we can speculate that themechanism
of STAR regulation by 14-3-3 may also be conserved across
species.
Based on immunoprecipitation andTATpeptide studies, the
significant increase in steroid levels at 2 h after cAMP treatment
may not be solely due to the induction in STAR levels but also to
the release of STAR from 14-3-3, which allows it to be phos-
phorylated at Ser-194. Although cAMP-induced phosphoryla-
tion of newly synthesized STAR is critical for the induction of
steroidogenesis, the 14-3-3-bound STARwould remain unphos-
phorylated and when released would provide additional pools of
STAR to be phosphorylated, thus sustaining for a longer period
of time the biological function of the protein. It is also impor-
tant to note that this binding site is a part of the STARTdomain
(residues 76–281). Studies byOmura and co-workers (35) have
shown that 14-3-3 can identify and bind to unfolded mito-
chondrial proteins, helping themmaintain this state. Indeed, in
that report, 14-3-3was suggested to be a part of themitochon-
drial import-stimulating factor (35, 64–66), which is a het-
erodimer of 14-3-3 with 14-3-3 (35). This area may prove to
be interesting for investigating in the mechanism of protein
import into mitochondria of steroidogenic cells.
Several studies since 1995 have dealt with the complexity of
STAR structure. The START domain is conserved inmammals
and plants, just like 14-3-3 proteins, and is shielded in the core
of the STAR protein rather than exposed (60, 63). Therefore,
few models were proposed to show the mechanism of binding
and dissociation of cholesterol to the START domain. Miller
and co-workers (26) have shown that, in acidic environments
such asmitochondrial membranes, the 62-amino acid N termi-
nus of STAR is more tightly folded than the START domain.
They further proposed a molten globule model for STAR func-
tion that suggests that STAR is partially unfolded and has lost
some of its tertiary structures while retaining its secondary
FIGURE 7. Proposed model for the negative regulatory role of 14-3-3 in steroidogenesis. A, under basal conditions, 14-3-3 is present in the form of
homodimers. B, after 15 min of cAMP treatment, PKA gets activated, and 14-3-3 homodimers dissociate, resulting in increased levels of 14-3-3monomers.
14-3-3monomers bind to STARat residues 191–196 in the STARTdomain andblock thePKAconsensus for Ser-194phosphorylation. Thus, STAR ismaintained
at partial rather than maximal activity. C, at 60 min of cAMP treatment, the levels of both STAR and 14-3-3 are increased significantly through translation of
pre-existingmRNA.D, at 2 h of stimulation, 14-3-3 levels are further increased leading to homodimerization, which likely carries out a dominant negative role
for 14-3-3 function. As a result, 14-3-3 dissociates from STAR, allowing Ser-194 to be phosphorylated by PKARI and further inducing STAR activity required
for maximal steroidogenesis.
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structure (array of  helices and  sheets). Therefore, choles-
terol can access the START domain in the loosely folded C
terminus (22, 26). The LeHoux (67) group also proposed a
model showing that under neutral pH conditions and in the
absence of cholesterol, a cavity is formed in the STARTdomain.
However, in the presence of cholesterol, this cavity is trans-
formed to a “closed” conformation, and a reversible unfolding
of the C-terminal helix of STAR takes place, providing access
for the cholesterol molecule. Both of these models emphasize
that STAR needs to be unfolded to allow for cholesterol bind-
ing. Therefore, because 14-3-3 binds to the START domain, it
might retain the unfolded structure, allowing cholesterol bind-
ing and subsequently altering STAR activity (22, 26, 68). There-
fore, we suggest that 14-3-3 dissociation from STAR is required
for proper folding of the semi-folded STAR. However, we cannot
rule out the possibility that 14-3-3 can also act by binding and
blocking STAR cleavage to the active form and/or binding to the
site containing Arg-182, which if mutated leads to congenital
adrenal hyperplasia.
Taken together, these results suggest amodel for the negative
regulatory role of 14-3-3 in steroidogenesis (Fig. 7). This
model proposes that after 15 min of hormonal stimulation,
14-3-3 homodimers dissociate, allowing 14-3-3 to interact
with its target STAR. This 14-3-3-STAR interaction blocks
the proper folding of STAR as the binding occurs at the START
domain and blocks the Ser-194 PKA phosphorylation site. Lack
of this phosphorylation prevents the induction of maximal
STARactivity, leaving the proteinwith only partial activity. The
association between 14-3-3 and STAR is maintained up to 60
min post-stimulation, whereas the levels of both proteins are
increased. However, the hormone-induced increase in 14-3-3
expression further leads to dimerization of this protein, which
manifests a dominant negative effect. This effect causes the
dissociation of 14-3-3 from STAR, leaving Ser-194 available
for phosphorylation by PKA and enabling maximal activity.
This system allows for the sustained production of steroids
within 2 h of hormonal stimulation. In conclusion, although it is
likely that 14-3-3 may interact in Leydig cells with various
proteins unrelated to the mechanism mediating the hormonal
induction of steroid biosynthesis, the data presented herein
demonstrate the determining role of 14-3-3 in this process.
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